Xin Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xin Zhang has a total of 119 co-authors. Here are the top co-authors by number of shared publications:
- Wei-Fen Xie
Department of Gastroenterology, Changzheng Hospital Naval Medical University Shanghai China
19 shared publications Chen-Hong Ding
Department of Gastroenterology, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China
14 shared publicationsFang Liu
Department of Gastroenterology, Changzheng Hospital, Naval Medical University, Shanghai 200003, China
7 shared publicationsFei Chen
Department of Gastroenterology Changzheng Hospital, Naval Medical University Shanghai China
7 shared publicationsKai Ding
Department of Gastroenterology, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China
6 shared publicationsMeng-Chao Xiao
Department of Gastroenterology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China
6 shared publications
Latest Publications
- 5 September 2026
- Published by Wiley in Liver International
- Vol. 46 (10) , e70846
Inhibition of Acetylation Activity of p300/ CBP Ameliorates Hepatic Steatosis Through Downregulation of ACSL4
Background & Aims: Metabolic dysfunction–associated steatotic liver disease (MASLD) is the most prevalent chronic liver disorder, with few optimal pharmacotherapies. Ongoing studies are providing evidence that histone acetylation contributes to the progression of MASLD. This study investigated the alterations of specific histone acetylation sites in MASLD tissues and the effects of B029‐2, a small‐molecule inhibitor targeting p300/CBP acetylation activity, in mouse models of progressive fatty liver disease. Methods: The acetylation of H3K27/H3K18/H3K9 was assessed in liver samples from MASLD patients and mice. The effect of the B029‐2 in MASLD was assessed in MASLD models. A ChIP assay was conducted to investigate the epigenetic regulatory mechanism of ACSL4. Hepatic‐specific Acsl4‐knockout and overexpression mice were generated to validate the role of ACSL4 in MASLD. Results: We observed a significant increase in p300 HAT activity, p300/CBP‐induced H3K18ac and H3K27ac levels in MASLD and B029‐2 markedly reduced hepatic steatosis in vitro and in vivo. Transcriptome analysis revealed that B029‐2 inhibited the expression of genes in the triglyceride biosynthetic process and long‐chain fatty‐acyl‐CoA biosynthetic process. ChIP assay showed that H3K18ac, H3K27ac and p300 bind to the promoter region of ACSL4 , and their binding is reduced by B029‐2 treatment. AAV‐mediated hepatic‐specific overexpression of Acsl4 attenuated the effect of B029‐2 on MASLD in mice, while hepatic‐specific Acsl4‐deficient in mice blocked the effect of B029‐2. Conclusions: p300/CBP‐mediated H3K18ac and H3K27ac regulate ACSL4‐dependent lipid biosynthesis in MASLD and might be a potential therapeutic target for the treatment of MASLD.
- 5 September 2026
- Published by Wiley in Liver International
- Vol. 46 (10) , e70846
Inhibition of Acetylation Activity of p300/ CBP Ameliorates Hepatic Steatosis Through Downregulation of ACSL4
Background & Aims: Metabolic dysfunction–associated steatotic liver disease (MASLD) is the most prevalent chronic liver disorder, with few optimal pharmacotherapies. Ongoing studies are providing evidence that histone acetylation contributes to the progression of MASLD. This study investigated the alterations of specific histone acetylation sites in MASLD tissues and the effects of B029‐2, a small‐molecule inhibitor targeting p300/CBP acetylation activity, in mouse models of progressive fatty liver disease. Methods: The acetylation of H3K27/H3K18/H3K9 was assessed in liver samples from MASLD patients and mice. The effect of the B029‐2 in MASLD was assessed in MASLD models. A ChIP assay was conducted to investigate the epigenetic regulatory mechanism of ACSL4. Hepatic‐specific Acsl4‐knockout and overexpression mice were generated to validate the role of ACSL4 in MASLD. Results: We observed a significant increase in p300 HAT activity, p300/CBP‐induced H3K18ac and H3K27ac levels in MASLD and B029‐2 markedly reduced hepatic steatosis in vitro and in vivo. Transcriptome analysis revealed that B029‐2 inhibited the expression of genes in the triglyceride biosynthetic process and long‐chain fatty‐acyl‐CoA biosynthetic process. ChIP assay showed that H3K18ac, H3K27ac and p300 bind to the promoter region of ACSL4 , and their binding is reduced by B029‐2 treatment. AAV‐mediated hepatic‐specific overexpression of Acsl4 attenuated the effect of B029‐2 on MASLD in mice, while hepatic‐specific Acsl4‐deficient in mice blocked the effect of B029‐2. Conclusions: p300/CBP‐mediated H3K18ac and H3K27ac regulate ACSL4‐dependent lipid biosynthesis in MASLD and might be a potential therapeutic target for the treatment of MASLD.
- 3 November 2025
- Published by Springer Nature in Hepatology International
- Vol. 20 (3) , 775-789
SOX9 promotes hepatocyte proliferation via upregulating TGF-α expression during liver regeneration
Background The liver possesses a remarkable capacity for regeneration. Previous studies have shown that SOX9/HNF4α double-positive hepatocytes play a role in chronic liver injury. Furthermore, the deletion of HNF4α results in prolonged hepatocyte proliferation following partial hepatectomy. However, the precise role of SOX9 in liver regeneration remains poorly understood. Methods We established acute liver injury models using standard partial hepatectomy (sHx), extended partial hepatectomy (eHx), and intraperitoneal injection of carbon tetrachloride (CCl4). To investigate the interplay between HNF4α and SOX9, we employed hepatocyte-specific Hnf4α knockout (Hnf4αHKO) and Sox9 knockout (Sox9HKO) mice. We assessed how SOX9 influenced liver regeneration in Sox9HKO and SOX9-overexpressing (Sox9HOE) mice. Results Our study found that SOX9 expression was increased, while HNF4α expression decreased in the priming phase of acute liver injury. HNF4α suppressed SOX9 expression by upregulating miR-124/381 in hepatocytes. Deletion of SOX9 in hepatocytes resulted in a reduced liver-to-body weight ratio and impaired hepatocyte proliferation in both sHx- and CCl4-treated mice. Conversely, hepatocyte-specific SOX9 overexpression improved survival rates in eHx-treated mice. Single-nucleus RNA sequencing of liver tissue and bulk RNA sequencing of hepatocytes from sHx-treated Sox9HKO mice revealed that SOX9 upregulated TGF-α expression in hepatocytes. Co-culture experiments further indicated that SOX9 overexpression enhanced the hepatocyte proliferation by promoting TGF-α secretion. Importantly, inhibiting TGF-α-induced EGFR activation partially reduced the pro-proliferative effects of SOX9 on hepatocytes and the survival rates by SOX9 overexpression in eHx-treated mice. Conclusions Our findings revealed that HNF4α negatively regulates SOX9 and demonstrated that SOX9 promotes hepatocyte proliferation by upregulating TGF-α levels, ultimately enhancing liver regeneration. Graphical abstract
- 3 November 2025
- Published by Springer Nature in Hepatology International
- Vol. 20 (3) , 775-789
SOX9 promotes hepatocyte proliferation via upregulating TGF-α expression during liver regeneration
Background The liver possesses a remarkable capacity for regeneration. Previous studies have shown that SOX9/HNF4α double-positive hepatocytes play a role in chronic liver injury. Furthermore, the deletion of HNF4α results in prolonged hepatocyte proliferation following partial hepatectomy. However, the precise role of SOX9 in liver regeneration remains poorly understood. Methods We established acute liver injury models using standard partial hepatectomy (sHx), extended partial hepatectomy (eHx), and intraperitoneal injection of carbon tetrachloride (CCl4). To investigate the interplay between HNF4α and SOX9, we employed hepatocyte-specific Hnf4α knockout (Hnf4αHKO) and Sox9 knockout (Sox9HKO) mice. We assessed how SOX9 influenced liver regeneration in Sox9HKO and SOX9-overexpressing (Sox9HOE) mice. Results Our study found that SOX9 expression was increased, while HNF4α expression decreased in the priming phase of acute liver injury. HNF4α suppressed SOX9 expression by upregulating miR-124/381 in hepatocytes. Deletion of SOX9 in hepatocytes resulted in a reduced liver-to-body weight ratio and impaired hepatocyte proliferation in both sHx- and CCl4-treated mice. Conversely, hepatocyte-specific SOX9 overexpression improved survival rates in eHx-treated mice. Single-nucleus RNA sequencing of liver tissue and bulk RNA sequencing of hepatocytes from sHx-treated Sox9HKO mice revealed that SOX9 upregulated TGF-α expression in hepatocytes. Co-culture experiments further indicated that SOX9 overexpression enhanced the hepatocyte proliferation by promoting TGF-α secretion. Importantly, inhibiting TGF-α-induced EGFR activation partially reduced the pro-proliferative effects of SOX9 on hepatocytes and the survival rates by SOX9 overexpression in eHx-treated mice. Conclusions Our findings revealed that HNF4α negatively regulates SOX9 and demonstrated that SOX9 promotes hepatocyte proliferation by upregulating TGF-α levels, ultimately enhancing liver regeneration. Graphical abstract
- Open Access
- 1 November 2025
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 16 (2) , 913-929
Blocking TRIM47-mediated HNF4α degradation suppresses hepatocellular carcinoma progression
- 1 November 2025
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 16 (2) , 913-929
Open AccessBlocking TRIM47-mediated HNF4α degradation suppresses hepatocellular carcinoma progression
- 1 August 2025
- Published by Wiley in Liver International
- Vol. 45 (9) , e70227
Endothelial Tgfbr2 Deficiency Ameliorate Liver Fibrosis Through Regulating Angiocrine Signalling and Macrophage Accumulation
Background & Aims: Transforming growth factor (TGF)‐β signalling plays an indispensable role in promoting the activation of hepatic stellate cells and inducing epithelial‐mesenchymal transition of hepatocytes during liver fibrosis. Liver sinusoidal endothelial cells (LSECs) undergo capillarisation and promote inflammatory responses following liver injury. Here, we investigated the role of TGF‐β signalling in LSECs during liver fibrosis. Methods: Single‐cell RNA‐sequencing (scRNA‐seq) datasets from healthy individuals and patients with cirrhosis were analysed to evaluate the expression of TGF‐β signalling related genes. Endothelial cell‐specific Tgfbr2 ‐knockout mice were generated and experimental liver fibrosis was induced by carbon tetrachloride injection or choline‐deficient high‐fat diet. Liver fibrosis was evaluated by qPCR, western blotting, histology and immunostaining. Primary LSECs were isolated and gene expression was analysed by RNA sequencing. Hepatic inflammation was assessed by qPCR, immunostaining and flow cytometry. Results: ScRNA‐seq analysis based on GSE136103 showed TGFBR2 is elevated in LSECs from cirrhotic patients compared to healthy controls. LSEC‐specific Tgfbr2 depletion ameliorated injury‐induced LSEC capillarisation and endothelial‐to‐mesenchymal transition. RNA sequencing revealed that Tgfbr2 deficiency downregulated chemokine expression and reshaped angiocrine signalling in LSECs. Endothelial‐specific Tgfbr2 deletion inhibited pro‐inflammatory monocyte recruitment and attenuated hepatic inflammation during liver fibrosis. Furthermore, Tgfbr2 deletion in LSECs inhibited macrophage chemotaxis in vitro. Conclusions: Endothelial TGF‐β signalling aggravates injury‐induced liver fibrosis by promoting LSECs capillarisation, EndMT and proinflammatory monocyte recruitment. These findings show the potential of targeting TGFBR2 in LSECs to control liver fibrotic diseases.
- 1 August 2025
- Published by Wiley in Liver International
- Vol. 45 (9) , e70227
Endothelial Tgfbr2 Deficiency Ameliorate Liver Fibrosis Through Regulating Angiocrine Signalling and Macrophage Accumulation
Background & Aims: Transforming growth factor (TGF)‐β signalling plays an indispensable role in promoting the activation of hepatic stellate cells and inducing epithelial‐mesenchymal transition of hepatocytes during liver fibrosis. Liver sinusoidal endothelial cells (LSECs) undergo capillarisation and promote inflammatory responses following liver injury. Here, we investigated the role of TGF‐β signalling in LSECs during liver fibrosis. Methods: Single‐cell RNA‐sequencing (scRNA‐seq) datasets from healthy individuals and patients with cirrhosis were analysed to evaluate the expression of TGF‐β signalling related genes. Endothelial cell‐specific Tgfbr2 ‐knockout mice were generated and experimental liver fibrosis was induced by carbon tetrachloride injection or choline‐deficient high‐fat diet. Liver fibrosis was evaluated by qPCR, western blotting, histology and immunostaining. Primary LSECs were isolated and gene expression was analysed by RNA sequencing. Hepatic inflammation was assessed by qPCR, immunostaining and flow cytometry. Results: ScRNA‐seq analysis based on GSE136103 showed TGFBR2 is elevated in LSECs from cirrhotic patients compared to healthy controls. LSEC‐specific Tgfbr2 depletion ameliorated injury‐induced LSEC capillarisation and endothelial‐to‐mesenchymal transition. RNA sequencing revealed that Tgfbr2 deficiency downregulated chemokine expression and reshaped angiocrine signalling in LSECs. Endothelial‐specific Tgfbr2 deletion inhibited pro‐inflammatory monocyte recruitment and attenuated hepatic inflammation during liver fibrosis. Furthermore, Tgfbr2 deletion in LSECs inhibited macrophage chemotaxis in vitro. Conclusions: Endothelial TGF‐β signalling aggravates injury‐induced liver fibrosis by promoting LSECs capillarisation, EndMT and proinflammatory monocyte recruitment. These findings show the potential of targeting TGFBR2 in LSECs to control liver fibrotic diseases.
- Open Access
- 4 July 2025
- Published by Springer Nature in Cell Research
- Vol. 35 (9) , 687-690
Differentiation therapy with hepatocyte nuclear factor 4α for patients with hepatocellular carcinoma
- 4 July 2025
- Published by Springer Nature in Cell Research
- Vol. 35 (9) , 687-690
Open AccessDifferentiation therapy with hepatocyte nuclear factor 4α for patients with hepatocellular carcinoma
- Open Access
- 6 March 2025
- Published by Springer Nature in Cell Death & Disease
- Vol. 16 (1) , 1-14
PRMT3 drives PD-L1-mediated immune escape through activating PDHK1-regulated glycolysis in hepatocellular carcinoma
Aberrant expression of programmed death ligand-1 (PD-L1) facilitates tumor immune evasion. Protein arginine methyltransferase 3 (PRMT3), a member of type I PRMT family, mediates asymmetric dimethylarginine (ADMA) modification of various substrate proteins. This study investigates the role of PRMT3 in PD-L1-associated tumor immunosuppression in hepatocellular carcinoma (HCC). Hepatocyte-specific knockout of Prmt3 significantly suppressed HCC progression in DEN-CCL4-treated mice. Knockout of Prmt3 in HCC cells markedly increased CD8+ T cell infiltration, and reduced lactate production in tumors. PRMT3 interacted with pyruvate dehydrogenase kinase 1 (PDHK1), asymmetric dimethylation of PDHK1 at arginine 363 and 368 residues and increased its kinase activity. The R363/368 K mutant or inhibition of PDHK1 by JX06 blocked the effect of PRMT3 on lactate production. JX06 treatment also attenuated the tumor-promoting role of PRMT3 in HCC in vitro and in vivo. Furthermore, RNA-seq analysis revealed that knockout of PRMT3 downregulates the tumor-associated immune checkpoint, PD-L1, in tumor tissues. Chromatin immunoprecipitation (ChIP) assay demonstrated that PRMT3 promotes lactate-induced PD-L1 expression by enhancing the direct binding of histone H3 lysine 18 lactylation (H3K18la) to the PD-L1 promoter. Tissue microarray analysis showed a positive correlation between PRMT3 and PD-L1 expression in HCC patients. Anti-PD-L1 treatment reversed PRMT3-induced tumor growth and restored CD8+ T cell infiltration. Our research links PRMT3-mediated metabolic reprogramming and immune evasion, revealing that the PRMT3-PDHK1-lactate-PD-L1 axis may be a potential target for improving the efficacy of immunotherapy in HCC.
- 6 March 2025
- Published by Springer Nature in Cell Death & Disease
- Vol. 16 (1) , 1-14
Open AccessPRMT3 drives PD-L1-mediated immune escape through activating PDHK1-regulated glycolysis in hepatocellular carcinoma
Aberrant expression of programmed death ligand-1 (PD-L1) facilitates tumor immune evasion. Protein arginine methyltransferase 3 (PRMT3), a member of type I PRMT family, mediates asymmetric dimethylarginine (ADMA) modification of various substrate proteins. This study investigates the role of PRMT3 in PD-L1-associated tumor immunosuppression in hepatocellular carcinoma (HCC). Hepatocyte-specific knockout of Prmt3 significantly suppressed HCC progression in DEN-CCL4-treated mice. Knockout of Prmt3 in HCC cells markedly increased CD8+ T cell infiltration, and reduced lactate production in tumors. PRMT3 interacted with pyruvate dehydrogenase kinase 1 (PDHK1), asymmetric dimethylation of PDHK1 at arginine 363 and 368 residues and increased its kinase activity. The R363/368 K mutant or inhibition of PDHK1 by JX06 blocked the effect of PRMT3 on lactate production. JX06 treatment also attenuated the tumor-promoting role of PRMT3 in HCC in vitro and in vivo. Furthermore, RNA-seq analysis revealed that knockout of PRMT3 downregulates the tumor-associated immune checkpoint, PD-L1, in tumor tissues. Chromatin immunoprecipitation (ChIP) assay demonstrated that PRMT3 promotes lactate-induced PD-L1 expression by enhancing the direct binding of histone H3 lysine 18 lactylation (H3K18la) to the PD-L1 promoter. Tissue microarray analysis showed a positive correlation between PRMT3 and PD-L1 expression in HCC patients. Anti-PD-L1 treatment reversed PRMT3-induced tumor growth and restored CD8+ T cell infiltration. Our research links PRMT3-mediated metabolic reprogramming and immune evasion, revealing that the PRMT3-PDHK1-lactate-PD-L1 axis may be a potential target for improving the efficacy of immunotherapy in HCC.
- Open Access
- 2 January 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-14
Positive feedback between arginine methylation of YAP and methionine transporter SLC43A2 drives anticancer drug resistance
Yes-associated protein (YAP) activation confers resistance to chemotherapy and targeted therapy. Methionine participates in cellular processes by converting to methyl donor for the methylation of DNA, RNA and protein. However, it remains unclear whether methionine affects drug resistance by influencing YAP activity. In this study, we report that methionine deprivation remarkably suppresses the transcriptional activity of YAP–TEAD in cancer cells. Methionine promotes PRMT1-catalyzed asymmetric dimethylation at R124 of YAP (YAP R124me2a). Mimicking of YAP methylation abolishes the reduction effect of methionine-restricted diet on YAP-induced drug resistance. YAP activates the transcription of SLC43A2, the methionine transporter, to increase methionine uptake in cancer cells. Knockdown of SLC43A2 decreases the level of YAP R124me2a. BCH, the inhibitor of SLC43A2, sensitizes tumors to anticancer drugs. Thus, our results unravel the positive feedback between YAP R124 methylation and SLC43A2 that contributes to anticancer drug resistance. Disrupting this positive feedback could be a potential strategy for cancer therapy.
- 2 January 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-14
Open AccessPositive feedback between arginine methylation of YAP and methionine transporter SLC43A2 drives anticancer drug resistance
Yes-associated protein (YAP) activation confers resistance to chemotherapy and targeted therapy. Methionine participates in cellular processes by converting to methyl donor for the methylation of DNA, RNA and protein. However, it remains unclear whether methionine affects drug resistance by influencing YAP activity. In this study, we report that methionine deprivation remarkably suppresses the transcriptional activity of YAP–TEAD in cancer cells. Methionine promotes PRMT1-catalyzed asymmetric dimethylation at R124 of YAP (YAP R124me2a). Mimicking of YAP methylation abolishes the reduction effect of methionine-restricted diet on YAP-induced drug resistance. YAP activates the transcription of SLC43A2, the methionine transporter, to increase methionine uptake in cancer cells. Knockdown of SLC43A2 decreases the level of YAP R124me2a. BCH, the inhibitor of SLC43A2, sensitizes tumors to anticancer drugs. Thus, our results unravel the positive feedback between YAP R124 methylation and SLC43A2 that contributes to anticancer drug resistance. Disrupting this positive feedback could be a potential strategy for cancer therapy.
- Open Access
- 20 December 2024
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 000 (000) , 000
SOX9 Overexpression Ameliorates Metabolic Dysfunction-associated Steatohepatitis Through Activation of the AMPK Pathway
The transcription factor sex-determining region Y-related high-mobility group-box gene 9 (SOX9) plays a critical role in organ development. Although SOX9 has been implicated in regulating lipid metabolism in vitro, its specific role in metabolic dysfunction-associated steatohepatitis (MASH) remains poorly understood. This study aimed to investigate the role of SOX9 in MASH pathogenesis and explored the underlying mechanisms.
- 20 December 2024
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 000 (000) , 000
Open AccessSOX9 Overexpression Ameliorates Metabolic Dysfunction-associated Steatohepatitis Through Activation of the AMPK Pathway
The transcription factor sex-determining region Y-related high-mobility group-box gene 9 (SOX9) plays a critical role in organ development. Although SOX9 has been implicated in regulating lipid metabolism in vitro, its specific role in metabolic dysfunction-associated steatohepatitis (MASH) remains poorly understood. This study aimed to investigate the role of SOX9 in MASH pathogenesis and explored the underlying mechanisms.
- Open Access
- 5 December 2024
- Published by Springer Nature in Discover Oncology
- Vol. 15 (1) , 1-16
Cell-permeated peptide P-T3H2 inhibits malignancy on hepatocellular carcinoma through stabilizing HNF4α protein
Objectives Hepatocyte nuclear factor 4α (HNF4α) is a key regulator of hepatocyte function and has a strong therapeutic effect on hepatocellular carcinoma (HCC) by inducing the differentiation of hepatoma cell into hepatocytes. Our previous study showed that Tribbles homolog 3 (TRIB3) directly interacts with and promotes the degradation of HNF4α in non-alcoholic fatty liver disease (NAFLD). Disrupting the TRIB3–HNF4α interaction by a cell-permeating peptide, called P-T3H2, stabilized HNF4α protein. This study aimed to assess the anti-tumor impact of P-T3H2 in HCC. Methods The expression of TRIB3 and HNF4α was evaluated using western blot and immunohistochemistry (IHC). Hepatic functions and cellular senescence of HCC cells were evaluated through periodic acid-Schiff (PAS) staining, acetylated low-density lipoprotein (ac-LDL) uptake and senescence-associated β-galactosidase (SA-β-gal) activity staining, respectively. RNA-Seq analysis was performed to identify differentially expressed genes in Huh7 cells treated with P-T3H2. The impact of P-T3H2 on HCC malignancy was assessed in vitro and in vivo. Results TRIB3 exhibited a negative correlation with HNF4α in both human and mouse HCC tissues. The administration of P-T3H2 significantly inhibited the malignancy of HCC cells. Additionally, P-T3H2 stabilized HNF4α protein and facilitated the restoration of hepatic functions and the cellular senescence in HCC cells. RNA-Seq analysis demonstrated that P-T3H2 enhanced the transcriptional activity of HNF4α in HCC. Furthermore, P-T3H2 effectively suppressed the carcinogenesis and progression of HCC in mice. Conclusion P-T3H2 suppressed HCC progression through the stabilization of HNF4α protein and may be a promising therapeutic candidate for clinical application in the treatment of HCC.
- 5 December 2024
- Published by Springer Nature in Discover Oncology
- Vol. 15 (1) , 1-16
Open AccessCell-permeated peptide P-T3H2 inhibits malignancy on hepatocellular carcinoma through stabilizing HNF4α protein
Objectives Hepatocyte nuclear factor 4α (HNF4α) is a key regulator of hepatocyte function and has a strong therapeutic effect on hepatocellular carcinoma (HCC) by inducing the differentiation of hepatoma cell into hepatocytes. Our previous study showed that Tribbles homolog 3 (TRIB3) directly interacts with and promotes the degradation of HNF4α in non-alcoholic fatty liver disease (NAFLD). Disrupting the TRIB3–HNF4α interaction by a cell-permeating peptide, called P-T3H2, stabilized HNF4α protein. This study aimed to assess the anti-tumor impact of P-T3H2 in HCC. Methods The expression of TRIB3 and HNF4α was evaluated using western blot and immunohistochemistry (IHC). Hepatic functions and cellular senescence of HCC cells were evaluated through periodic acid-Schiff (PAS) staining, acetylated low-density lipoprotein (ac-LDL) uptake and senescence-associated β-galactosidase (SA-β-gal) activity staining, respectively. RNA-Seq analysis was performed to identify differentially expressed genes in Huh7 cells treated with P-T3H2. The impact of P-T3H2 on HCC malignancy was assessed in vitro and in vivo. Results TRIB3 exhibited a negative correlation with HNF4α in both human and mouse HCC tissues. The administration of P-T3H2 significantly inhibited the malignancy of HCC cells. Additionally, P-T3H2 stabilized HNF4α protein and facilitated the restoration of hepatic functions and the cellular senescence in HCC cells. RNA-Seq analysis demonstrated that P-T3H2 enhanced the transcriptional activity of HNF4α in HCC. Furthermore, P-T3H2 effectively suppressed the carcinogenesis and progression of HCC in mice. Conclusion P-T3H2 suppressed HCC progression through the stabilization of HNF4α protein and may be a promising therapeutic candidate for clinical application in the treatment of HCC.
- Open Access
- 15 June 2024
- Published by Springer Nature in Cell Death & Disease
- Vol. 15 (6) , 1-13
Tripartite motif 8 promotes the progression of hepatocellular carcinoma via mediating ubiquitination of HNF1α
Tripartite motif 8 (TRIM8) is an E3 ligase that plays dual roles in various tumor types. The biological effects and underlying mechanism of TRIM8 in hepatocellular carcinoma (HCC) remain unknown. Hepatocyte nuclear factor 1α (HNF1α) is a key transcriptional factor that plays a significant role in regulating hepatocyte differentiation and liver function. The reduced expression of HNF1α is a critical event in the development of HCC, but the underlying mechanism for its degradation remains elusive. In this study, we discovered that the expression of TRIM8 was upregulated in HCC tissues, and was positively correlated with aggressive tumor behavior of HCC and shorter survival of HCC patients. Overexpression of TRIM8 promoted the proliferation, colony formation, invasion, and migration of HCC cells, while TRIM8 knockdown or knockout exerted the opposite effects. RNA sequencing revealed that TRIM8 knockout suppresses several cancer-related pathways, including Wnt/β-catenin and TGF-β signaling in HepG2 cells. TRIM8 directly interacts with HNF1α, promoting its degradation by catalyzing polyubiquitination on lysine 197 in HCC cells. Moreover, the cancer-promoting effects of TRIM8 in HCC were abolished by the HNF1α-K197R mutant in vitro and in vivo. These data demonstrated that TRIM8 plays an oncogenic role in HCC progression through mediating the ubiquitination of HNF1α and promoting its protein degradation, and suggests targeting TRIM8-HNF1α may provide a promising therapeutic strategy of HCC.
- 15 June 2024
- Published by Springer Nature in Cell Death & Disease
- Vol. 15 (6) , 1-13
Open AccessTripartite motif 8 promotes the progression of hepatocellular carcinoma via mediating ubiquitination of HNF1α
Tripartite motif 8 (TRIM8) is an E3 ligase that plays dual roles in various tumor types. The biological effects and underlying mechanism of TRIM8 in hepatocellular carcinoma (HCC) remain unknown. Hepatocyte nuclear factor 1α (HNF1α) is a key transcriptional factor that plays a significant role in regulating hepatocyte differentiation and liver function. The reduced expression of HNF1α is a critical event in the development of HCC, but the underlying mechanism for its degradation remains elusive. In this study, we discovered that the expression of TRIM8 was upregulated in HCC tissues, and was positively correlated with aggressive tumor behavior of HCC and shorter survival of HCC patients. Overexpression of TRIM8 promoted the proliferation, colony formation, invasion, and migration of HCC cells, while TRIM8 knockdown or knockout exerted the opposite effects. RNA sequencing revealed that TRIM8 knockout suppresses several cancer-related pathways, including Wnt/β-catenin and TGF-β signaling in HepG2 cells. TRIM8 directly interacts with HNF1α, promoting its degradation by catalyzing polyubiquitination on lysine 197 in HCC cells. Moreover, the cancer-promoting effects of TRIM8 in HCC were abolished by the HNF1α-K197R mutant in vitro and in vivo. These data demonstrated that TRIM8 plays an oncogenic role in HCC progression through mediating the ubiquitination of HNF1α and promoting its protein degradation, and suggests targeting TRIM8-HNF1α may provide a promising therapeutic strategy of HCC.